This website is intended for UK healthcare professionals only Log in | Register

News and views

November 2017 Br J Cardiol 2017;24:130

Primary Care Cardiovascular Society announces its relaunch

Kathryn E Griffith (Secretary of the PCCS and Cardiovascular Lead for the Vale of York CCG) writes about the newly formed Primary Care Cardiovascular Society....

November 2017 Br J Cardiol 2017;24:130

New series on insights from the Bradford Healthy Hearts project

We are delighted to announce a new series for 2018 on the award-winning Bradford Healthy Hearts Project. This collaborative improvement programme, which involves primary care, secondary care, public health and commissioning, was inspired by failure… in that Bradford, compared to the rest of England and Wales, had an unenviably poor record in terms of cardiovascular disease morbidity and mortality. The project was delivered mainly in primary care and was based on three streams of work covering atrial fibrillation, hypertension and lipid management. ...

November 2017 Br J Cardiol 2017;24:136 Meeting report

Cholesterol – a problem solved?

The 31st HEART UK Annual Medical and Scientific Conference took place at the University of Warwick from 5th – 7th July 2017. This year’s conference focused on cholesterol management in the future and reflected the current period of change in health care delivery and expectation. Jaqui Walker reports the meeting’s highlights....

November 2017 Br J Cardiol 2017;24:135

New test hopes to boost med school recruitment

A new advisory careers test has been designed with the aim of transforming the recruitment of potential doctors. It is hoped the test will address the shortage of GPs and emergency doctors in the NHS, and give pupils from all backgrounds equal opportunities. Historically state sector students have been at a disadvantage over private school pupils....

November 2017 Br J Cardiol 2017;24:135

Cardiff Met launches stroke research hub

Around 7,400 individuals will have a stroke in Wales each year, with 66,000 currently living with the after effects of a stroke. It is estimated that 70 % of stroke cases could be avoided....

November 2017 Br J Cardiol 2017;24:135

Rivaroxaban label update for extended VTE prevention

The European Commission (EC) has approved an update to the label of rivaroxaban (Xarelto®, Bayer) to include a 10 mg once daily dose for the extended prevention of recurrent venous thromboembolism (VTE). This label update applies to patients who have already received at least six months of standard anticoagulation therapy, and provides clinicians with an additional treatment option alongside the 20 mg once daily dose already licensed in this indication....

November 2017 Br J Cardiol 2017;24:135

ESC congress returns to London

The ESC decision is a huge vote of confidence in London as a leading centre for medical research. London overcame stiff competition from other key European cities in winning the event for 2021. When the ESC last came to London in 2015, it generated £100 million of economic benefit for the city, attracting more than 32,700 delegates from 140 countries....

November 2017 Br J Cardiol 2017;24:155

Anticoagulation group rebrands and partners with BJC

We are delighted that the BJC is now an offcial partner with Anticoagulation UK....

October 2017 Online First

News from the European Society of Cardiology congress 2017

This year’s meeting of the European Society of Cardiology (ESC) provided results from a wide range of clinical trials on anticoagulation, lipid lowering, diet and cardiovascular outcomes, and the use of oxygen in acute myocardial infarction. There were also exciting findings with a novel anti-inflammatory agent, targeted at atherosclerosis. Held in Barcelona, Spain, from 26th – 30th August 2017, our report – written by the BJC team and Drs Kevin Cheng and Chris Allen – focuses on the implications of these new data, as well as providing overviews on electrolyte disturbances and iron deficiency in patients with systolic heart failure....

October 2017 Meeting report

ESC 2017: CANTOS – a focus on inflammation and atherosclerosis

A consistent criticism of the ESC congress in recent years has been that, outside of the chronic heart failure arena at least, the late breaker sessions have lacked headline-grabbing, big-hitting landmark trials. Not this year. “This is our 1994!” proclaimed chief investigator, Paul Ridker (Brigham and Women’s Hospital, Boston, USA), on presentation of the results of CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study), drawing parallels with the practice-changing impact of the 4S (Scandinavian Simvastatin Survival Study) trial, which demonstrated the efficacy of statins for the first time and opened the door to lipid lowering as a highly prosperous therapeutic pathway in cardiovascular disease in the process....

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now